AlcoChange智能手机数字疗法改善酒精相关肝病结局的真实世界实施:个体随机平行组对照试验方案
该方案描述一项多中心、两臂平行组、个体随机对照试验,在英格兰至多18家NHS医院招募400例酒精相关肝病患者,1:1随机比较常规照护联合AlcoChange(智能手机应用加数字呼气分析仪)与单纯常规照护,主要结局为随机化后180天通过时间线回溯法评估的戒酒或低风险饮酒(每周<14单位)比例。
要点
- 纳入确诊酒精相关肝病、被建议戒酒且有意愿、拥有智能手机的18岁及以上成人。
- 主要结局为随机化后180天戒酒或低风险饮酒(每周<14单位)的患者比例。
- 次要结局包括多个时间点自报饮酒量、肝病严重程度、健康相关生活质量、医疗资源利用和成本效果。
核心结论
- 该试验将评估AlcoChange在减少酒精相关肝病患者饮酒及酒精相关损害方面的真实世界疗效和成本效果。
研究设计与样本
- 多中心、两臂、平行组、个体随机对照试验,从英格兰至多18家NHS医院招募400例患者并按1:1随机。
- 比较常规照护(由医院酒精照护团队进行复核和简短干预)与常规照护联合AlcoChange。
- 采用混合方法开发试验方案,包括变革理论框架和为时间线回溯法评估定制的培训材料。
主要发现
- 初步数据显示AlcoChange在减少酒精使用方面具有潜在疗效。
- 主要结局为随机化后180天戒酒或报告低风险饮酒(每周<14单位)的患者比例,采用时间线回溯法评估。
临床怎么用
- 作者认为该试验将为数字疗法用于酒精使用障碍和肝病的临床实践与政策提供有价值证据。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Deaths from alcohol-related liver disease (ARLD) are rising in the UK, representing a significant public health crisis. Effective interventions are urgently needed to reduce alcohol consumption and improve outcomes for individuals with ARLD. While behaviour change interventions (BCIs) are effective, their scalability is limited. Digital therapeutics offer a promising avenue for delivering BCIs remotely and at scale. AlcoChange, a novel digital therapeutic combining a smartphone app and digital breathalyser, delivers personalised BCIs based on patient triggers. Preliminary data suggest its potential efficacy in reducing alcohol use. METHODS: This is a multi-centre, two-arm, parallel-group, individually randomised controlled trial comparing usual care (review by a hospital Alcohol Care Team and brief intervention) with usual care plus AlcoChange in patients with ARLD. POPULATION: Adults aged 18 years or older with a diagnosis of ARLD (including cirrhosis, fibrosis, steatohepatitis, or recent alcoholic hepatitis) who have been advised to abstain from alcohol and intend to do so, and who have access to a smartphone. INTERVENTION: Usual care plus AlcoChange, comprising a smartphone app and digital breathalyser delivering personalised behaviour change techniques. COMPARISON: Usual care alone. OUTCOME: The primary outcome is the proportion of patients abstinent or reporting low-risk alcohol consumption (< 14 units/week) at 180 days post-randomisation, assessed using the Timeline Follow-Back (TLFB) method. Secondary outcomes include self-reported alcohol use at various time points, liver disease severity, health-related quality of life, healthcare resource utilisation, and cost-effectiveness. Four hundred participants will be recruited from up to 18 NHS hospitals in England and randomised 1:1. A mixed-methods approach was used to develop the trial protocol, including a theory of change framework and bespoke training materials for the TLFB assessment. DISCUSSION: This trial will evaluate the real-world efficacy and cost-effectiveness of AlcoChange in reducing alcohol consumption and alcohol-related harm in individuals with ARLD. The study addresses the urgent need for scalable interventions to combat the rising burden of ARLD in the UK. The pragmatic design and mixed methods approach to implementation aim to enhance the generalizability and impact of the findings. The trial will provide valuable evidence to inform clinical practice and policy regarding the use of digital therapeutics for alcohol use disorder and liver disease.
引用
- Cook A, Bamber J, Chinnery F, et al. Real world implementation of AlcoChange, a smartphone digital therapeutic to improve outcomes from alcohol-related liver disease: protocol for an individually randomised parallel group controlled trial. Trials. 2025. PMID: 41174638. doi:10.1186/s13063-025-09005-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。